Arcutis Biotherapeutics Inc (NASDAQ: ARQT) open the trading on Wednesday, with a bit cautious approach as it glided -0.95% to $8.34, before settling in for the price of $8.42 at the close. Taking a more long-term approach, ARQT posted a 52-week range of $1.76-$13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 303.42%. Meanwhile, its Annual Earning per share during the time was -48.07%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 60.14%. This publicly-traded company’s shares outstanding now amounts to $116.89 million, simultaneously with a float of $101.14 million. The organization now has a market capitalization sitting at $974.86 million. At the time of writing, stock’s 50-day Moving Average stood at $9.40, while the 200-day Moving Average is $7.36.
Arcutis Biotherapeutics Inc (ARQT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arcutis Biotherapeutics Inc’s current insider ownership accounts for 13.47%, in contrast to 99.72% institutional ownership. According to the most recent insider trade that took place on Aug 19 ’24, this organization’s insider sold 1,728 shares at the rate of 8.29, making the entire transaction reach 14,318 in total value, affecting insider ownership by 194,859.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Revenue Records
Arcutis Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 60.14% and is forecasted to reach -1.13 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.80% through the next 5 years, which can be compared against the -48.07% growth it accomplished over the previous five years trading on the market.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). It’s Quick Ratio in the last reported quarter now stands at 8.19. The Stock has managed to achieve an average true range (ATR) of 0.72. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.38.
In the same vein, ARQT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.18, a figure that is expected to reach -0.41 in the next quarter, and analysts are predicting that it will be -1.13 at the market close of one year from today.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
[Arcutis Biotherapeutics Inc, ARQT] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic%D was recorded 16.50% While, its Average True Range was 0.70.
Raw Stochastic average of Arcutis Biotherapeutics Inc (ARQT) in the period of the previous 100 days is set at 21.84%, which indicates a major rise in contrast to 20.60% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 69.10% that was lower than 75.66% volatility it exhibited in the past 100-days period.
